Moody’s could raise Salix

Moody's Investors Service said it placed the ratings of Salix Pharmaceuticals, Ltd. under review for upgrade, including the B1 corporate family rating, B1-PD probability of default rating, Ba1 senior secured ratings and B2 senior unsecured rating.

The speculative grade liquidity rating was affirmed at SGL-3.

This action follows the announcement that Valeant Pharmaceuticals International, Inc. made an offer to acquire Salix for about $14.5 billion including debt.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.